Print this page
-
Open-Label Dose-Finding and Dose-Expansion Study to Evaluate the Safety, Expansion, Persistence, and Clinical Activity of UCART20x22 (in Subjects with Relapsed or Refractory B-Cell Non-Hodgkin s Lymphoma (B-NHL).
Protocol: 012208Principal Investigator:
-
Ira Braunschweig
Applicable Disease Sites: Non-Hodgkin's Lymphoma -
Antibodies to Commensal Bacteria in Lymphoma Pathogenesis
Protocol: 012209Principal Investigator:
-
Yun Kyoung Tiger
Applicable Disease Sites: Non-Hodgkin's Lymphoma -
A Phase 3 Randomized Study Comparing Talquetamab SC in Combination With Daratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination With Daratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone (DPd), in Participants With Relapsed or Refractory Multiple Myeloma who Have Received
at Least 1 Prior Line of Therapy.
Protocol: 012301Principal Investigator:
-
Mansi R Shah
Applicable Disease Sites: Multiple Myeloma -
Phase 1, Open-label, Dose-escalation and Expansion Study of TNB-486, a Bispecific Antibody Targeting CD19 in Subjects with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma.
Protocol: 012302Principal Investigator:
-
Matthew Matasar
Applicable Disease Sites: Non-Hodgkin's Lymphoma -
A Phase 1 Study to Assess Safety and Tolerability of REGN5837, an Anti-CD22 x Anti-CD28 Costimulatory Bispecific Monoclonal Antibody, in Combination with Odronextamab, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients with Aggressive B-Cell Non-Hodgkin Lymphomas (ATHENA-1)
Protocol: 012303Principal Investigator:
-
Matthew Matasar
Applicable Disease Sites: Non-Hodgkin's Lymphoma -
Phase II study to assess the efficacy of combined tafasitamab and rituximab in front-line treatment of post-transplant lymphoproliferative disorder
Protocol: 012306Principal Investigator:
-
Joanna Rhodes
Applicable Disease Sites: Non-Hodgkin's Lymphoma -
A Phase 3, Open Label, Randomized Study Comparing the Efficacy and Safety of Odronextamab (REGN1979), an anti CD20 × anti-CD3 Bispecific Antibody, in Combination with CHOP (O-CHOP) versus Rituximab in Combination with CHOP (R-CHOP) in Previously Untreated Participants with Diffuse Large B-cell Lymphoma (DLBCL) (OLYMPIA-3).
Protocol: 012307Principal Investigator:
-
Matthew Matasar
Applicable Disease Sites: Non-Hodgkin's Lymphoma -
Phase 1/2 Study of Linvoseltamab (Anti-BCMA x Anti-CD3 Bispecific Antibody) in Previously Untreated Patients with Symptomatic Multiple Myeloma (Linker-MM4 Study)
Protocol: 012310Principal Investigator:
-
Mansi R Shah
Applicable Disease Sites: Multiple Myeloma -
Phase 1/Expansion Study of Tazemetostat Plus Belinostat for the Treatment of Relapsed or Refractory Lymphoma.
Protocol: 012312Principal Investigator:
-
Yun Kyoung Tiger
Applicable Disease Sites: Non-Hodgkin's Lymphoma -
Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study.
Protocol: 012314Principal Investigator:
-
Joanna Rhodes
Applicable Disease Sites: Lymphoid Leukemia -
A Phase 3 Randomized Clinical Study of MK-4280A Coformulated Favezelimab MK-4280 plus Pembrolizumab MK-3475 Versus Physician's Choice Chemotherapy in PD-(L)1-Refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (KEYFORM-008).
Protocol: 012315Principal Investigator:
-
Matthew Matasar
Applicable Disease Sites: Hodgkin's Lymphoma -
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma.
Protocol: 012316Principal Investigator:
-
Joanna Rhodes
Applicable Disease Sites: Non-Hodgkin's Lymphoma -
A Phase 1b Multicenter, Open-label, Study of JNJ-90009530, an Autologous Anti-CD20
CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non- Hodgkin Lymphoma
Protocol: 012317Principal Investigator:
-
Matthew Matasar
Applicable Disease Sites: Non-Hodgkin's Lymphoma -
A Phase 3, Randomized, Open-Label Study Comparing the Efficacy and Safety of the Combination of Beleodaq-CHOP or Folotyn-COP to the CHOP Regimen Alone in Newly Diagnosed Patients with Peripheral T-Cell Lymphoma
Protocol: 012320Principal Investigator:
-
Yun Kyoung Tiger
Applicable Disease Sites: Non-Hodgkin's Lymphoma -
First-in-Human Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of the BTK Degrader, ABBV-101, in
Participants with B-cell Malignancies
Protocol: 012321Principal Investigator:
-
Joanna Rhodes
Applicable Disease Sites: Non-Hodgkin's Lymphoma -
Testing of Immune Synapse Characteristics During Therapy of Multiple Myeloma
Protocol: 012322Principal Investigator:
-
Mansi R Shah
Applicable Disease Sites: Multiple Myeloma